Search

Background: Fatigue, cognitive impairment, anxiety, depression, and sleep disturbance are cancer-related behavioral symptoms (CRBS) that may persist years after early-stage breast cancer (BC), affecting quality of life. We aimed at generating a predictive model of long-term CRBS clusters among BC survivors four years post-diagnosis., Methods: Patients with early-stage BC were included from the CANcer TOxicity (NCT01993498). Our outcome was the proportion of patients reporting CRBS clusters four years post-diagnosis (≥3 severe CRBS). Predictors, including clinical, behavioral, and treatment-related characteristics, Behavioral Symptoms Score (BSS; 1 point per severe CRBS at diagnosis) and a pro-inflammatory cytokine (IL-1b, IL-6, TNFα)-genetic risk score, were tested using multivariable logistic regression, implementing bootstrapped Augmented Backwards Elimination. A two-sided p-value < 0.05 defined statistical significance., Results: In the development cohort (N = 3555), 642 patients (19.0%) reported a cluster of CRBS at diagnosis and 755 (21.2%) did so four years post-diagnosis. Younger age (adjusted Odds Ratio [aOR] for 1-year decrement: 1.012; 95% Confidence Interval [CI] 1.003-1.020); previous psychiatric disorders (aOR vs no: 1.27; 95% CI 1.01-1.60); and BSS (aOR ranged from 2.17 [1.66-2.85] for BSS = 1 vs 0 to 12.3 [7.33-20.87] for BSS = 5 vs 0) were predictors of reporting a cluster of CRBS (AUC 0.73 [95%CI 0.71-0.75]). Genetic risk score was not predictive of CRBS. Results were confirmed in the validation cohort (N = 1533)., Conclusion: Younger patients with previous psychiatric disorders and higher baseline symptom burden have greater risk of long-term clusters of CRBS. Our model might be implemented in clinical pathways to improve management and test the effectiveness of risk mitigation interventions among breast cancer survivors., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Endocrine therapy plays a crucial role in the treatment of women with hormone receptor-positive breast cancer. However, non-adherence remains a frequent issue known to negatively impact survival. Based on a comprehensive literature review, this article explores the terminologies employed to describe adherence and methods used for its assessment, the adherence data reported with adjuvant endocrine therapy with targeted therapies, the determinants of adherence or non-adherence, and finally, tested solutions to address it. The results show that a better understanding of the causes of non-adherence would help to better identify patients at risk, and to develop personalized intervention programs capable of improving adherence to adjuvant endocrine therapy. In light of the literature, interventions are likely to require a multimodal approach and integration into our future healthcare pathways., (Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

In communication technologies such as digital watermarking, wireless sensor networks (WSNs), and visual light communication (VLC), error-correcting codes are crucial. The Enhanced Hadamard Error-Correcting Code (EHC), which is based on 2D Hadamard Basis Images, is a novel error correction technique that is presented in this study. This technique is used to evaluate the effectiveness of the video watermarking scheme. Even with highly sophisticated embedding techniques, watermarks usually fail to resist such comprehensive attacks because of the extraordinarily high compression rate of approximately 1:200 that is frequently employed in video dissemination. It can only be used in conjunction with a sufficient error-correcting coding method. This study compares the efficacy of the well-known Reed-Solomon Code with this novel technique, the Enhanced Hadamard Error-Correcting Code (EHC), in maintaining watermarks in embedded videos. The main idea behind this newly created multidimensional Enhanced Hadamard Error-Correcting Code is to use a 1D Hadamard decoding approach on the 2D base pictures after they have been transformed into a collection of one-dimensional rows. Following that, the image is rebuilt, allowing for a more effective 2D decoding procedure. Using this technique, it is possible to exceed the theoretical error-correcting capacity threshold of ⌊dmin-12⌋ bits, where dmin is the Hamming distance. It may be possible to achieve better results by converting the 2D EHC into a 3D format. The new Enhanced Hadamard Code is used in a video watermarking coding scheme to show its viability and efficacy. The original video is broken down using a multi-level interframe wavelet transform during the video watermarking embedding process. Low-pass filtering is applied to the video stream in order to extract a certain frequency range. The watermark is subsequently incorporated using this filtered section. Either the Reed-Solomon Correcting Code or the Enhanced Hadamard Code is used to protect the watermarks. The experimental results show that EHC far outperforms the RS Code and is very resilient against severe MPEG compression.

Objectives: Tumor molecular genotyping plays a key role in improving the management of advanced thyroid cancers. Molecular tests are classically performed on Formalin-Fixed Paraffin-Embedded (FFPE) carcinoma tissue. However alternative molecular testing strategies are needed when FFPE tumoral tissue is unavailable. The objective of our study was to retrospectively assess the performance of targeted DNA and RNA-based Next Generation Sequencing (NGS) on the fine needle aspirate from thyroid cancer cervical recurrences to determine if this strategy is efficient in clinical practice., Design/methods: A retrospective study of 33 patients who had had DNA and/or RNA-based NGS on ultrasound (US)-guided fine needle aspirates of cervical thyroid cancer recurrences in our Department from July 2019 to September 2022., Results: In total, 34 DNA and 32 RNA-based NGS analyses were performed. Out of the 34 DNA-based NGS performed, 27 (79%) were conclusive allowing the identification of an oncogenic driver for 18 patients (53%). The most common mutation (n = 13) was BRAF c.1799T>A. Out of the 32 RNA-based NGS performed, 26 were interpretable (81%) and no gene fusion was found. The identification of a BRAFV600E mutation was decisive for one patient in our series, who was prescribed dabrafenib and trametinib., Conclusions: NGS performed on fine needle aspirates of neck lymph node metastases enabled the identification of an oncogenic driver alteration in 53% of the cases in our series of advanced thyroid cancer patients and could significantly alter patient management.